Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
17,912
Total Claims
$1.4M
Drug Cost
672
Beneficiaries
$2,055
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,389 General Practice providers
-95%
Opioid rate vs peers
0.1% vs 2.5% avg
+82%
Cost per patient vs peers
$2,055 vs $1,128 avg
+54%
Brand preference vs peers
12.9% vs 8.4% avg
Opioid Prescribing
0.1%
Opioid Rate
21
Opioid Claims
$120
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,279 claims · $1.1M
Generic: 15,342 claims · $309K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Insulin Glargine,hum.Rec.Anlog | 213 | $120K |
| Dapagliflozin Propanediol | 108 | $100K |
| Apixaban | 82 | $76K |
| Sitagliptin Phos/Metformin Hcl | 68 | $67K |
| Sitagliptin Phosphate | 45 | $52K |
| Rivaroxaban | 40 | $50K |
| Levothyroxine Sodium | 342 | $39K |
| Insulin Glargine/Lixisenatide | 43 | $38K |
| Empaglifloz/Linaglip/Metformin | 42 | $30K |
| Empagliflozin | 33 | $26K |
| Candesartan Cilexetil | 193 | $26K |
| Insulin Nph Hum/Reg Insulin Hm | 50 | $26K |
| Empagliflozin/Linagliptin | 24 | $25K |
| Insulin Lispro | 33 | $24K |
| Insulin Glargine,hum.Rec.Anlog | 45 | $21K |
Prescribing Profile
Patient Profile
73
Avg Age
54%
Female
1.91
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data